Long-term intrathecal ziconotide for chronic pain: an open-label study

Journal of Pain and Symptom Management
Lynn R WebsterMark S Wallace

Abstract

This open-label multicenter study evaluated the long-term safety and efficacy of intrathecal ziconotide and included 78 patients with chronic pain who had completed one of two previous ziconotide clinical trials. Each patient's initial ziconotide dose was based on his or her dose from the study of origin and was adjusted as necessary on the basis of adverse events and analgesic effect. The median ziconotide dose was 6.48 mcg/day (range, 0.00-120.00 mcg/day) at the Initial Visit and ranged from 5.52 to 7.20 mcg/day across all study visits. The most commonly reported new adverse events that were considered ziconotide related were memory impairment (11.3%); dizziness, nystagmus, and speech disorder (8.5% each); nervousness and somnolence (7.0% each); and abnormal gait (5.6%). There was no evidence of increased adverse event incidence at higher cumulative ziconotide doses. Elevations in creatine kinase were noted, but the proportion of patients with creatine kinase elevations did not change from the Initial Visit to the Termination Visit (4.1% each). Stable mean Visual Analog Scale of Pain Intensity scores during the three years of the study suggested no evidence of increased pain intensity with increased duration of ziconotide exp...Continue Reading

References

Jan 1, 1995·Annual Review of Pharmacology and Toxicology·G P Miljanich, J Ramachandran
Jan 8, 2004·JAMA : the Journal of the American Medical Association·Peter S StaatsDavid Ellis
Dec 8, 2004·Current Medicinal Chemistry·G P Miljanich
May 24, 2006·Journal of Pain and Symptom Management·Richard L RauckUNKNOWN Ziconotide 301 Study Group
Dec 7, 2007·The Journal of Pain : Official Journal of the American Pain Society·Robert H DworkinStojan Zavisic
Jan 30, 2008·Anesthesia and Analgesia·Mark S WallaceUNKNOWN Ziconotide 98-022 Study Group
Jan 1, 2008·Neuromodulation : Journal of the International Neuromodulation Society·David J EllisUNKNOWN Elan Study 95-002 Group
Apr 1, 2006·Neuromodulation : Journal of the International Neuromodulation Society·Mark S WallaceUNKNOWN Ziconotide Nonmalignant Pain Study 96-002 Group

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Pain and Headache Reports·Erin F Lawson, Mark S Wallace
Jun 8, 2012·Neuromodulation : Journal of the International Neuromodulation Society·Robert M Levy
Mar 30, 2013·Expert Opinion on Pharmacotherapy·Jason E Pope, Timothy R Deer
Jul 12, 2011·Expert Opinion on Investigational Drugs·Terry PextonMark S Wallace
Jul 1, 2009·Current Medical Research and Opinion·S DewildeG D H Maclaine
Feb 10, 2016·Neuromodulation : Journal of the International Neuromodulation Society·Gladstone C McDowell, Jason E Pope
Dec 15, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Petra Vayne-BossertJanet Hardy
Jul 31, 2013·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Krishna KumarWei Tang
Aug 18, 2009·Pain Practice : the Official Journal of World Institute of Pain·Richard L RauckJames M North
May 29, 2012·Pain Practice : the Official Journal of World Institute of Pain·George MiljanichMichael Saulino
Jun 8, 2012·British Journal of Pharmacology·V Nimmrich, G Gross
Oct 6, 2009·Chemico-biological Interactions·Jon-Paul BinghamZachary L Bergeron
Feb 25, 2015·Neuromodulation : Journal of the International Neuromodulation Society·Jason E Pope, Timothy R Deer
Feb 7, 2015·Neuromodulation : Journal of the International Neuromodulation Society·Salim M HayekI Elias Veizi
Jan 9, 2014·Journal of Pain & Palliative Care Pharmacotherapy·Timothy Strigenz
Aug 6, 2016·Neuromodulation : Journal of the International Neuromodulation Society·Julia PrusikJulie G Pilitsis
Nov 28, 2013·Pharmaceuticals·Gene GurkoffRobert Berman
Mar 16, 2018·Postgraduate Medicine·Gladstone C McDowell, Joseph Winchell
Jan 4, 2017·Neuromodulation : Journal of the International Neuromodulation Society·Timothy R DeerNagy Mekhail
Jan 4, 2017·Neuromodulation : Journal of the International Neuromodulation Society·Timothy R DeerNagy Mekhail
Aug 24, 2018·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Timothy R DeerGladstone C McDowell
Feb 16, 2021·Expert Opinion on Drug Safety·Alan ChalilCharles E Argoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.